Sarepta director granted 16,875 RSUs

Chambers Michael Andrew reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Chambers Michael Andrew reported acquisition or exercise transactions in this Form 4 filing.

Sarepta Therapeutics director Michael Andrew Chambers reported an equity award of 16,875 shares of common stock in the form of restricted stock units. The RSUs were granted at no cash cost per share and will vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, provided it occurs at least 50 weeks after the prior annual meeting. Following this grant, Chambers holds 27,535 shares directly, in addition to 476,492 shares held indirectly through a revocable trust.

Insider Trade Summary

Grant/Award: 16,875 shares

Grant/Award 2 txns

Insider Chambers Michael Andrew

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	16,875	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 27,535 shares (Direct); Common Stock — 476,492 shares (Indirect, By Revocable Trust)

Footnotes (1)

1. F1. The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.

Key Figures

RSU grant size: 16,875 shares Grant price per share: $0.00 per share Direct holdings after grant: 27,535 shares +2 more

5 metrics

RSU grant size 16,875 shares Restricted stock units granted to director

Grant price per share $0.00 per share Stated price for RSU award

Direct holdings after grant 27,535 shares Common stock directly owned post-transaction

Indirect trust holdings 476,492 shares Common stock held by revocable trust

RSU-to-share ratio 1 RSU : 1 share Each RSU represents one share of common stock

Key Terms

restricted stock units ("RSUs"), revocable trust, annual meeting of stockholders

3 terms

restricted stock units ("RSUs") financial

"The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

revocable trust financial

"total_shares_following_transaction ... ownership_type "indirect" and nature_of_ownership "By Revocable Trust""

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

annual meeting of stockholders financial

"The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Sarepta Therapeutics (SRPT) report for Michael Andrew Chambers?

Sarepta Therapeutics reported that director Michael Andrew Chambers received 16,875 restricted stock units as an equity award. Each RSU represents one share of common stock and was granted at no cash cost per share, reflecting compensation rather than an open-market purchase.

How many Sarepta Therapeutics (SRPT) shares does Michael Andrew Chambers hold after this Form 4?

After the reported award, Michael Andrew Chambers directly holds 27,535 shares of Sarepta Therapeutics common stock. He also has an indirect holding of 476,492 shares through a revocable trust, giving insight into both his direct and trust-related positions reported in this filing.

What are the vesting terms of Michael Andrew Chambers’ new RSUs at Sarepta Therapeutics (SRPT)?

The 16,875 restricted stock units granted to Michael Andrew Chambers vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders. That annual meeting must occur at least 50 weeks after the immediately preceding year’s annual meeting, according to the filing.

Is Michael Andrew Chambers’ Sarepta Therapeutics (SRPT) RSU award a market purchase of shares?

No, the RSU award is compensation, not a market purchase. Chambers received 16,875 restricted stock units at a stated price of $0.00 per share, meaning the shares are granted by the company and will be delivered upon vesting, subject to the specified vesting conditions.

How is the revocable trust related to Michael Andrew Chambers’ Sarepta Therapeutics (SRPT) holdings?

The filing shows 476,492 Sarepta shares held indirectly by Michael Andrew Chambers through a revocable trust. This indicates an additional position reported as indirect ownership separate from his 27,535 directly held shares, giving a fuller view of his disclosed equity exposure to the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 08:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chambers Michael Andrew

(Last) (First) (Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		A		16,875	A	(1)	27,535	D
Common Stock								476,492	I	By Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Michael Chambers	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)